Epstein-barr virus and posttransplant lymphoproliferative disorder in solid organ transplantation

American Journal of Transplantation

Volumn 13, Issue SUPPL.4, 2013, Pages 107-120

  Allen, U D ^a,b,c   Preiksaitis, J K ^d  

^a Department of Pediatrics and Health Policy Management and Evaluation ^*  (Canada)

^b HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Epstein Barr virus (EBV); lymphoproliferation, PTLD; rituximab; viral infection

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; GANCICLOVIR; IMMUNOGLOBULIN; LYMPHOCYTE ANTIBODY; METHOTREXATE; OKT 3; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINCRISTINE; VINDESINE;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; BLOOD EXAMINATION; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GRAFT INFECTION; GRAFT RECIPIENT; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGICAL TOLERANCE; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LYMPHOPROLIFERATIVE DISEASE; MEDICAL SOCIETY; NATURAL KILLER CELL; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN TRANSPLANTATION; OVERALL SURVIVAL; PATIENT CARE; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SALIVA; SEROLOGY; SOLID ORGAN TRANSPLANTATION; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT RESPONSE; VIROGENESIS; VIRUS DETECTION; VIRUS IMMUNITY; VIRUS LOAD;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; EPSTEIN-BARR VIRUS INFECTIONS; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; ORGAN TRANSPLANTATION; PROGNOSIS; RISK FACTORS;

EID: 84874837177     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12104     Document Type: Article

References (110)

1. Green M., Management of Epstein-Barr virus-induced posttransplant lymphoproliferative disease in recipients of solid organ transplantation. Am J Transplant 2001; 1: 103-108.
2. Nalesnik MA., The diverse pathology of post-transplant lymphoproliferative disorders: The importance of a standardized approach. Transpl Infect Dis 2001; 3: 88-96.
3. Preiksaitis JK,. New developments in the diagnosis and management of posttransplantation lympholiferative disorders in solid organ transplant recipients. Clin Infect Dis 2004; 39: 1016-1023.
4. Nourse JP, Jones K, Gandhi MK,. Epstein-Barr virus-related post-transplant lymphoproliferative disorders: Pathogenetic insights for targeted therapy. Am J Transplant 2011; 11: 888-895.
5. Forte E, Luftig MA,. The role of microRNAs in Epstein-Barr virus latency and lytic reactivation. Microbes Infect 2011; 13: 1156-1167.
6. Thorley-Lawson D, Gross A,. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 2004; 350: 1328-1337.
7. Snow A, Martinez O,. Epstein-Barr virus: Evasive maneuvers in the development of PTLD. Am J Transplant 2007; 7: 271-277.
8. Hadinoto V, Shapiro M, Greenough TC, et al. On the dynamics of acute EBV infection and the pathogenesis of infectious mononucleosis. Blood 2008; 111: 1420-1427.
9. Vereide DT, Sugden B,. Lymphomas differ in their dependence on Epstein-Barr virus. Blood 2011; 117: 1977-1985.
10. Parker A, Bowles K, Bradley A, et al. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients-BCSH and BTS Guidelines. Br J Haematol 2010; 149: 675-692.
11. Parker A, Bowles K, Bradley A, et al. Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients-BCSH and BTS Guidelines. Br J Haematol 2010; 149: 693-705.
12. Allen UD,. The ABC of Epstein-Barr virus infections-Hot topics in infection and immunity in children. Adv Exp Med Biol 2005; 568: 25-39.
13. Caillard S, Lamy FX, Quelen C, et al. Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: Report of the French registry and analysis of subgroups of lymphomas. Am J Transplant 2012; 12: 682-693.
14. Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson I,. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients. Nephrol Dial Transplant 2012; 27: 2971-2979.
15. Opelz G, Dohler B., Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004; 4: 222-230.
16. Swerdlow S,. T-cell and NK-cell posttransplantation lymphoproliferative disorders. Am J Clin Pathol 2007; 127: 887-895.
17. Doucette K, Dicken B, Bigam D, Preiksaitis J,. Epstein-Barr virus viral load monitoring in high risk, EBV donor seropositive (D+), recipient seronegative (R-), adult and pediatric solid organ transplant (SOT) patients decreases early posttransplant lymphoproliferative disorder (PTLD). Am J Transplant 2010; 10 (Suppl 4): 472.
18. Shigeta T, Imodaone K, Sakamoto S, et al. Epstein-Barr virus infection after pediatric living-related liver transplantation-mana-gement and risk factors. Transplant Proc 2010; 42: 4178-4180.
19. Gulley ML, Swinnen LJ, Plaisance KT Jr., Schnell C, Grogan TM, Schneider BG,; Southwest Oncology Group. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: Implications for immune-based therapy. Transplantation 2003; 76: 959-964.
20. Olagne J, Caillard S, Gaub MP, Chenard MP, Moulin B,. Post-transplant lymphoproliferative disorders: Determination of donor/recipient origin in a large cohort of kidney recipients. Am J Transplant 2011; 11: 1260-1269.
21. Walker RC, Marshall WF, Strickler JG, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995; 20: 1346-1353.
22. Cockfield SM., Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis 2001; 3: 70-78.
23. Caillard S, Dharnidharka V, Agoda L, et al. Posttransplant lymphoproliferative disorders and renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005; 80: 1233-1243.
24. Webber SA, Green M,. Post-transplant lymphoproliferative disorders and malignancy. In:, Fine RN, Webber SA, Olthoff KM, Kelly DA, Harmon WE, eds. Pediatric solid organ transplantation. Malden: Blackwell Publishing, 2007; pp. 114-123.
25. Stojanova J, Caillard S, Rousseau A, Marquet P,. Post-transplant lymphoproliferative disease (PTLD): Pharmacological, virological and other determinants. Pharmacol Res 2011; 63: 1-7.
26. Allen U, Hébert D, Moore D, Dror Y, Wasfy S and the Canadian PTLD Survey Group-1998. Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplant recipient, 1988-97: A Canadian multi-centre experience. Pediatr Transplant 2001; 5: 198-203.
27. Dharnidharka VR, Lamb KE, Gregg JA, Meier-Kriesche HU., Associations between EBV Serostatus and organ transplant type in PTLD risk: An analysis of the SRTR National Registry Data in the United States. Am J Transplant 2012; 12: 976-983.
28. Allen UD, Farkas G, Hébert D, et al. Risk factors for posttransplant lymphoproliferative disease (PTLD) in pediatric patients. Pediatr Transplant 2005; 9: 450-455.
29. Dharnidharka VR,. Epidemiology of PTLD. In:, Dharnidharka VR, Green M, Webber S, eds. Post-transplant lymphoproliferative disorders. Berlin Heidelberg: Springer, 2010; pp. 17-28.
30. Pestana JO, Grinyo JM, Vanrenterghem Y, et al. Three-year outcomes from BENEFIT-EXT: A phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant 2012; 12: 630-639.
31. Vincenti F, Larsen CP, Alberu J, et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant. 2012; 12: 210-217.
32. Larsen CP, Grinyó J, Medina-Pestana J, et al. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation 2010; 90: 1528-1535.
33. Jonigk D, Laenger F, Maegel L, et al. Molecular and clinicopathological analysis of Epstein-Barr virus-associated posttransplant smooth muscle tumors. Am J Transplant 2012; 12: 1908-1917.
34. Humar A, Malkan G, Moussa G, et al. Human herpesvirus-6 is associated with cytomegalovirus reactivation in liver transplant recipients. J Infect Dis 2000; 181: 1450-1453.
35. Barton M, Wasfy S, Hébert D, et al, and the EBV and Associated Viruses Collaborative Research Group. Exploring beyond viral load testing for EBV lymphoproliferation: Role of serum IL6 and IgE assays as adjunctive tests. Pediatr Transplant 2009; 13: 990-998.
36. Engels EA, Preiksaitis JK, Zingone A, Landgren O,. Circulating antibody free light chains and risk of posttransplant lymphoproliferative disorder. Am J Transplant 2012; 12: 1268-1274.
37. Haque T, Chaggar T, Schafers J, Atkinson C, McAulay K, Crawford D,. Soluble CD30: A serum marker for Epstein-Barr virus-associated lymphoproliferative diseases. J Med Virol 2011; 83: 311-316.
38. Schiffer L, Henke-Gendo C, Wilsdorf N, et al. CXCL13 as a novel marker for diagnosis and disease monitoring in pediatric PTLD. Am J Transplant 2012; 12: 1610-1617.
39. Carpentier L, Tapiero B, Alvarez F, et al. Epstein-Barr virus (EBV) early-antigen serologic testing in conjunction with peripheral blood EBV DNA load as a marker for risk of posttransplantation lymphoproliferativ disease. J Infect Dis 2003; 188: 1853-1864.
40. Preiksaitis JK, Diaz-Mitoma F, Mirzayans F, et al. Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: Relationship to immunosuppressive therapy, serologic responses, and the risk of posttransplant lymphoproliferative disorder. J Infect Dis 1992; 166: 986-994.
41. Young L, Alfieri C, Hennessy K, et al. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N EngI J Med 1989; 321: 1080-1085.
42. Fanaian N, Cohen C, Waldrop S, et al. EBER: Automated in situ hybridization (ISH) vs. manual ISH and immunohistochemistry (IHC) for detection of EBV in pediatric lymphoproliferative disorders. Pediatr Dev Pathol 2009; 12: 195-199.
43. Meru N, Davison S, Whitehead L, et al. Epstein-Barr virus infection in paediatric liver transplant recipients: Detection of the virus in post-transplant tonsillectomy specimens. Mol Pathol 2001; 54: 264-269.
44. Preiksaitis JK,. Epstein-Barr viral load testing: Role in prevention, diagnosis and management of posttransplant lymphoproliferative disorders. In:, Dharnidharka VR, Green M, Webber S, eds. Post-transplant lymphoproliferative disorders. Berlin Heidelberg: Springer, 2010; pp. 45-68.
45. Hayden RT, Hokanson KM, Pounds SB, et al. Multicenter comparison of different real-time PCR assays for quantitative detection of Epstein-Barr virus. J Clin Microbiol 2008; 46: 157-163.
46. Preiksaitis JK, Pang XL, Fox JD, et al. Inter-laboratory comparison of Epstein-Barr virus (EBV) viral load assays. Am J Transplant 2009; 9: 269-279.
47. Hakim H, Gibson C, Pan J, et al. Comparison of various blood compartments and reporting units for the detection and quantification of Epstein-Barr virus (EBV) in peripheral blood. J Clin Microbiol 2007; 45: 2151-2155.
48. De Paoli P, Pratesi C, Bortolin MT., The Epstein Barr virus DNA levels as a tumor marker in EBV-associated cancers. J Cancer Res Clin Oncol 2007; 133: 809-815.
49. Ruf S, Behnke-Hall K, Gruhn B, et al. Comparison of six different specimen types for Epstein-Barr viral load quantification in peripheral blood of pediatric patients after heart transplantation or after allogeneic hematopoietic stem cell transplantation. J Clin Virol 2012; 53: 186-194.
50. Stevens SJC, Verschuuren EAM, Verkuulen AWM, et al. Role of Epstein-Barr virus DNA load monitoring in prevention and early detection of post-transplant lymphoproliferative disease. Leuk Lymphoma 2002; 43: 831-840.
51. Weinstock DM, Ambrossi GG, Brennan C, et al. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: An approach in development. Bone Marrow Transplant 2006; 37: 539-546.
52. Tsai DE, Douglas L, Andreadis C, et al. EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: Results of a two-arm prospective trial. Am J Transplant 2008; 8: 1016-1024.
53. Gartner BC, Fischinger J, Schafer H, et al. Epstein-Barr viral load as a tool to diagnose and monitor post-transplant lymphoproliferative disease: Recent results. Cancer Res 2002; 159: 49-54.
54. Whelass SA, Gulley ML, Raab-Traub N, et al. Post-transplantation lymphoproliferative disease. Epstein-Barr virus DNA levels, HLA-A3 and survival. Am J Respir Crit Care Med 2008; 178: 1060-1065.
55. Stevens SJC, Verschuuren EAM, Pronk I, et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001; 97: 1165-1171.
56. Wagner HJ, Wessel M, Jabs W, et al. Patients at risk for development of posttransplant lymphoproliferative disorder: Plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction. Transplantation 2001; 72: 1012-1019.
57. Michelson P, Watkins B, Webber SA, Wadowsky R, Michaels MG., Screening for PTLD in lung and heart-lung transplant recipients by measuring EBV DNA load in bronchoalveolar lavage fluid using real time PCR. Pediatr Transplant 2008; 12: 464-468.
58. Bauer CC, Jaksch P, Aberle SW, et al. Relationship between cytomegalovirus DNA load in epithelial lining fluid and plasma of lung transplant recipients and analysis of coinfection with Epstein-Barr virus and human herpesvirus 6 in the lung compartment. J Clin Microbiol 2007; 45: 324-328.
59. Weinberg A, Li S, Palmer M, Tyler KL,. Quantitative CSF PCR in Epstein-Barr virus infections of the central nervous system. Ann Neurol 2002; 52: 543-548.
60. Smets F, Latinne D, Bazin H, et al. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation 2002; 73: 1603-1610.
61. Macedo C, Zeevi A, Bentlejewski C, et al. The impact of EBV load on T-cell immunity inpediatric thoracic transplant recipients. Transplantation 2009; 88: 123-128.
62. Qu L, Green M, Webber S, Reyes J, Ellis D, Rowe D., Epstein-Barr virus genes expression in the peripheral blood of transplant recipients with persistent circulating virus loads. J Infect Dis 2000; 182: 1013-1021
63. Bianchi E, Pascual M, Nicod M, et al. Clinical usefulness of FDG-PET/CT scan imaging in the management of posttransplant lymphoproliferative disease. Transplantation 2008; 85: 707-712.
64. McCormack L, Hany TI, Hübner M, et al. How useful is PET/CT imaging in the management of post-transplant lymphoproliferative disease after liver transplantation? Am J Transplant 2006; 6: 1731-1736.
65. Swerdlow SH, Webber SA, Ferry JA, et al. A post-transplant lymphoproliferative disorders. WHO classification of tumors of haematopoietic and lymphoid tissues, 4th Ed. Lyons: International Agency for Research on Cancer/WHO, 2008.
66. Murphy SB., Classification, staging and end results of treatment of childhood non-Hodgkins lymphoma: Dissimilarities with lymphoma in adults. Semin Oncol 1980; 7: 332-339.
67. Funch DP, Waler AM, Schneidr G, et al. Ganciclovir and acyclovir reduce the risk of post-transplant lympoproliferative disorder in renal transplant recipients. Am J Transplant 2005; 5: 2894-2900.
68. Humar A, Hébert D, Davies D, et al. A multi-center randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against EBV related post-transplant lymphoproliferative disorder (PTLD) in high-risk solid organ transplant recipients. Transplantation 2006; 81: 856-861.
69. Green M, Michaels MG, Katz BZ, et al. CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients. Am J Transplant 2006; 6: 1906-1912.
70. Opelz G, Daniel V, Naujokat C, et al. Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hogkin lymphoma: A multicentre retrospective analysis. Lancet Oncol 2007; 8: 212-218.
71. Goodman L., EBV conference establishes goals for defining disease-related EBV subtypesfor vaccinedevelopment. Zheng 2009; 28: 1233-1235.
72. Rees L, Tizard EJ, Morgan AJ, et al. A phase I trial of Epstein-Barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation. Transplantation 2009; 88: 1025-1029.
73. McDiarmid SV, Jordan S, Kim GS, et al. Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998; 66: 1604-1611. Erratum in: Transplantation 1999; 68: 909.
74. Lee TC, Savoldo B, Rooney CM, et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant 2005; 5: 2222-2228.
75. Martin SI, Dodson B, Wheeler C, Davis J, Pesavent T, Bumgardner GL., Monitoring infection with Epstein-Barr Virus among seromismatch adult renal transplant recipients Am J Transplant 2011; 11: 1058-1063.
76. van Esser JW, Niesters HG, van der Holt B, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002; 99: 4364-4369.
77. Savoldo B, Gross JA, Hammer MM, et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTL). Blood 2006; 108: 2942-2949.
78. Comoli P, Labirio M, Basso S, et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 2002; 99: 2592-2598.
79. Savoldo B, Goss JA, Hammer MM, et al. Treatment of solid organ transplant recipients with autologous Epstein-Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 2006; 108: 2942-2949.
80. Reshef R, Vardhanabhuti S, Luskin MR, et al. Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder. Am J Transplant 2011; 11: 336-347.
81. Webber SA, Green M., Post-transplant lymphoproliferative disorders and malignancy. In:, Fine RA, Webber SA, Olthoff KM, Kelly DA, Harmon WE, eds. Pediatric solid organ transplantation, 2nd Ed. Malden: Blackwell Publishing, 2007; pp 114-123.
82. Dror Y, Greenberg M, Taylor G, et al. Lymphoproliferative disorders after organ transplantation in children. Transplantation 1999; 67: 990-998.
83. Preiksaitis JK, Cockfield SM,. Epstein-Barr virus and lymphoproliferative disease after hematopoietic stem cell or solid organ transplantation. In:, Bowden RA, Ljungman P, Paya CV, eds. Transplant infections, 2nd Ed. Philadelphia: Lippincott, Williams, and Wilkins, 2003; pp. 326-349.
84. Perrine S, Hermine O, Small T, et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 2007; 109: 2571-2578.
85. Reid E., Bortezomib-induced Epstein-Barr virus and Kaposi sarcoma herpesvirus lytic gene expression: Oncolytic strategies. Curr Opin Oncol 2011; 23: 482-487.
86. Trappe R, Oertel S, Leblond V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): The prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2012; 13: 196-206.
87. Evens AM, David KA, Helenowski I, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: Outcomes and prognostic factors in the modern era. J Clin Oncol 2010; 28: 1038-1046.
88. González-Barca E, Domingo-Domenech E, Capote FJ, et al. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. Haematologica 2007; 92: 1489-1494.
89. Choquet S, Trappe R, Leblond V, Jäger U, Davi F, Oertel S,. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders following solid organ transplantation. Haematologica 2007; 92: 273-274.
90. Trappe RU, Choquet S, Reinke P, et al. Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after upfront chemotherapy: The role of single-agent rituximab. Transplantation 2007; 84: 1708-1712.
91. Gross TG, Bucuvalas JC, Park JR, et al. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol 2005; 23: 6481-6488.
92. Gross TG, Orjuela MA, Perkins SL, et al. Low-dose chemotherapy and rituximab for post-transplant lymphoproliferative disease (PTLD): A Children's Oncology Group report. Am J Transplant 2012; 12: 3069-3075.
93. Haque T, Wilkie G, Jones M, et al. Allogeneic cytotoxic T-cell therapy for EBV positive posttransplantation lymphoproliferative disease: Results of a phase 2 multicellular clinical trial. Blood 2007; 110: 1123-1131.
94. Davis CL,. Interferon and cytotoxic chemotherapy for the treatment of post-transplant lymphoproliferative disorder. Transpl Infect Dis 2001; 3: 108-118.
95. Haddad E, Paczesny S, Leblond V, et al. Treatment of B- lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: A multicenter phase 1-2 clinical trial. Blood 2001; 97: 1590-1597.
96. Jagadeesh D, Woda BA, Draper J, Evens AM,. Post transplant lymphoproliferative disorders: Risk, classification, and therapeutic recommendations. Curr Treat Options Oncol 2012; 13: 122-136.
97. Cavaliere R, Petroni G, Lopes MB, Schiff D,. The International Primary Central Nervous System Lymphoma Collaborative Group. Primary central nervous system post-transplantation lymphoproliferative disorder. Cancer 2010; 116: 863-870.
98. Patrick A, Wee A, Hedderman A, Wilson D, Weiss J, Govani M,. High-dose intravenous rituximab for multifocal, monomorphic primary central nervous system posttransplant lymphoproliferative disorder. J Neuro Oncol 2011; 103: 739-743.
99. Green M, Cacciarelli TV, Mazariegos GV, et al. Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease. Transplantation 1998; 66: 1641-1644.
100. Yang J, Tao Q, Flinn IW, et al. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: Disappearance after rituximab therapy does not predict clinical response. Blood 2000; 96: 4055-4063.
101. Oertel S, Trappe RU, Zeidler K, et al. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course. Ann Hematol 2006; 85: 478-484.
102. van Esser JWJ, Niesters HGM, Thijsen SFT, et al. Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation. Br J Haematol 2001; 113: 814-821.
103. Gotoh K, Ito Y, Ohta R, et al. Immunologic and virologic analyses in pediatric liver transplant recipients with chronic high Epstein-Barr virus loads. J Infect Dis 2010; 202: 461-469.
104. Moran J, Carr M, Waters A, et al. Epstein-Barr virus gene expression, human leukocyte antigen alleles and chronic high viral loads in pediatric renal transplant patients. Transplantation 2011; 92: 328-333.
105. + T cells from asymptomatic pediatric thoracic transplant patients carrying chronic high EBV loads display contrasting features: Activated phenotype exhausted function. J Immunol 2011; 186: 5854-5862.
106. Bingler MA, Feingold B, Miller SA, et al. Chronic high Epstein-Barr viral load state and risk for late-onset posttransplant lymphoproliferative disease/lymphoma in children. Am J Transplant 2008; 8: 442-445.
107. Lau AH, Soltys K, Sindhi RK, Bond G, Mazariegos GV, Green M,. Chronic high Epstein-Barr viral load carriage in pediatric small bowel transplant recipients. Pediatr Transplant 2010; 14: 549-553.
108. Green M, Soltys K, Rowe DT, et al. Chronic high Epstein-Barr viral load carriage in pediatric liver transplant recipients. Pediatr Transplant 2009; 13: 319-323.
109. D'Antiga L, Del Rizzo M, Mengoli C, Cillo U, Guariso G, Zancan L,. Sustained Epstein-Barr virus detection in paediatric liver transplantation. Insights into the occurrence of late PTLD. Liver Transpl 2007; 13: 343-348.
110. Green M, Soltys K, Rowe DT, Webber SA, Mazareigos G,. Chronic high Epstein-Barr viral load carriage in pediatric liver transplant recipients. Pediatr Transplant 2009; 13: 319-323.